Last reviewed · How we verify
Intralipid 20%
At a glance
| Generic name | Intralipid 20% |
|---|---|
| Also known as | 20% I.V. Fat Emulsion, Lipid Emulsion 20%, Lipofundin 20%, soybean oil, N-6 polyunsaturated fatty acids atty acids |
| Sponsor | Emory University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction (PHASE2)
- Low Dose Fat-Induced Insulin Resistance (EARLY_PHASE1)
- Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses (PHASE2)
- Intralipid® 20% for Reversal of Local Anesthetics (PHASE4)
- Does Intralipid Infusion Can Reverse the Spinal Anesthesia Effect in Day Case Surgery? (NA)
- Role of Intralipid in Management of Organophosphorus Poisoning (PHASE2, PHASE3)
- Insulin and Insulin Pulses During Fasting (NA)
- A Phase 2 Study of Methylene Blue Photodynamic Therapy for Treatment of Breast Abscesses (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intralipid 20% CI brief — competitive landscape report
- Intralipid 20% updates RSS · CI watch RSS
- Emory University portfolio CI